nodes	percent_of_prediction	percent_of_DWPC	metapath
Dabigatran etexilate—CES2—Irinotecan—pancreatic cancer	0.288	0.41	CbGbCtD
Dabigatran etexilate—CES1—Tamoxifen—pancreatic cancer	0.13	0.185	CbGbCtD
Dabigatran etexilate—CES1—Irinotecan—pancreatic cancer	0.1	0.142	CbGbCtD
Dabigatran etexilate—UGT1A9—Irinotecan—pancreatic cancer	0.0607	0.0864	CbGbCtD
Dabigatran etexilate—UGT2B7—Epirubicin—pancreatic cancer	0.059	0.0841	CbGbCtD
Dabigatran etexilate—F2—hepatic artery—pancreatic cancer	0.0227	0.281	CbGeAlD
Dabigatran etexilate—F2—portal vein—pancreatic cancer	0.0197	0.244	CbGeAlD
Dabigatran etexilate—ABCB1—Tamoxifen—pancreatic cancer	0.0128	0.0183	CbGbCtD
Dabigatran etexilate—ABCB1—Gemcitabine—pancreatic cancer	0.011	0.0157	CbGbCtD
Dabigatran etexilate—ABCB1—Erlotinib—pancreatic cancer	0.0109	0.0155	CbGbCtD
Dabigatran etexilate—ABCB1—Irinotecan—pancreatic cancer	0.00984	0.014	CbGbCtD
Dabigatran etexilate—ABCB1—Docetaxel—pancreatic cancer	0.00721	0.0103	CbGbCtD
Dabigatran etexilate—ABCB1—Sunitinib—pancreatic cancer	0.00718	0.0102	CbGbCtD
Dabigatran etexilate—UGT2B15—gall bladder—pancreatic cancer	0.00619	0.0764	CbGeAlD
Dabigatran etexilate—ABCB1—Doxorubicin—pancreatic cancer	0.00538	0.00766	CbGbCtD
Dabigatran etexilate—UGT2B15—islet of Langerhans—pancreatic cancer	0.00406	0.0501	CbGeAlD
Dabigatran etexilate—F2—gall bladder—pancreatic cancer	0.00339	0.0419	CbGeAlD
Dabigatran etexilate—CES1—gall bladder—pancreatic cancer	0.00311	0.0384	CbGeAlD
Dabigatran etexilate—UGT2B15—pancreas—pancreatic cancer	0.00285	0.0352	CbGeAlD
Dabigatran etexilate—CES2—islet of Langerhans—pancreatic cancer	0.00248	0.0306	CbGeAlD
Dabigatran etexilate—UGT2B15—digestive system—pancreatic cancer	0.00244	0.0301	CbGeAlD
Dabigatran etexilate—NQO2—islet of Langerhans—pancreatic cancer	0.00222	0.0273	CbGeAlD
Dabigatran etexilate—UGT1A9—digestive system—pancreatic cancer	0.00185	0.0228	CbGeAlD
Dabigatran etexilate—CES2—pancreas—pancreatic cancer	0.00174	0.0215	CbGeAlD
Dabigatran etexilate—NQO2—pancreas—pancreatic cancer	0.00156	0.0192	CbGeAlD
Dabigatran etexilate—UGT2B7—digestive system—pancreatic cancer	0.00149	0.0184	CbGeAlD
Dabigatran etexilate—CES2—digestive system—pancreatic cancer	0.00149	0.0184	CbGeAlD
Dabigatran etexilate—F2—digestive system—pancreatic cancer	0.00133	0.0165	CbGeAlD
Dabigatran etexilate—CES1—digestive system—pancreatic cancer	0.00123	0.0151	CbGeAlD
Dabigatran etexilate—ABCB1—islet of Langerhans—pancreatic cancer	0.000478	0.0059	CbGeAlD
Dabigatran etexilate—ABCB1—pancreas—pancreatic cancer	0.000336	0.00415	CbGeAlD
Dabigatran etexilate—ABCB1—digestive system—pancreatic cancer	0.000287	0.00354	CbGeAlD
Dabigatran etexilate—Pain in extremity—Epirubicin—pancreatic cancer	0.000171	0.00118	CcSEcCtD
Dabigatran etexilate—Skin disorder—Gemcitabine—pancreatic cancer	0.000171	0.00117	CcSEcCtD
Dabigatran etexilate—Nervous system disorder—Fluorouracil—pancreatic cancer	0.00017	0.00116	CcSEcCtD
Dabigatran etexilate—Thrombocytopenia—Fluorouracil—pancreatic cancer	0.000169	0.00116	CcSEcCtD
Dabigatran etexilate—Dizziness—Tamoxifen—pancreatic cancer	0.000169	0.00116	CcSEcCtD
Dabigatran etexilate—Hypotension—Irinotecan—pancreatic cancer	0.000169	0.00116	CcSEcCtD
Dabigatran etexilate—Dizziness—Erlotinib—pancreatic cancer	0.000168	0.00115	CcSEcCtD
Dabigatran etexilate—Hypotension—Gemcitabine—pancreatic cancer	0.000164	0.00113	CcSEcCtD
Dabigatran etexilate—Cardiac disorder—Docetaxel—pancreatic cancer	0.000163	0.00112	CcSEcCtD
Dabigatran etexilate—Vomiting—Tamoxifen—pancreatic cancer	0.000163	0.00112	CcSEcCtD
Dabigatran etexilate—Cardiac failure—Doxorubicin—pancreatic cancer	0.000163	0.00112	CcSEcCtD
Dabigatran etexilate—Hypotension—Fluorouracil—pancreatic cancer	0.000162	0.00111	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Sunitinib—pancreatic cancer	0.000162	0.00111	CcSEcCtD
Dabigatran etexilate—Rash—Tamoxifen—pancreatic cancer	0.000161	0.00111	CcSEcCtD
Dabigatran etexilate—Dermatitis—Tamoxifen—pancreatic cancer	0.000161	0.00111	CcSEcCtD
Dabigatran etexilate—Vomiting—Erlotinib—pancreatic cancer	0.000161	0.00111	CcSEcCtD
Dabigatran etexilate—Dyspnoea—Irinotecan—pancreatic cancer	0.000161	0.00111	CcSEcCtD
Dabigatran etexilate—Headache—Tamoxifen—pancreatic cancer	0.00016	0.0011	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Gemcitabine—pancreatic cancer	0.00016	0.0011	CcSEcCtD
Dabigatran etexilate—Rash—Erlotinib—pancreatic cancer	0.00016	0.0011	CcSEcCtD
Dabigatran etexilate—Dermatitis—Erlotinib—pancreatic cancer	0.00016	0.0011	CcSEcCtD
Dabigatran etexilate—Angiopathy—Docetaxel—pancreatic cancer	0.00016	0.00109	CcSEcCtD
Dabigatran etexilate—Dyspepsia—Irinotecan—pancreatic cancer	0.000159	0.00109	CcSEcCtD
Dabigatran etexilate—Immune system disorder—Docetaxel—pancreatic cancer	0.000159	0.00109	CcSEcCtD
Dabigatran etexilate—Headache—Erlotinib—pancreatic cancer	0.000159	0.00109	CcSEcCtD
Dabigatran etexilate—Gastrointestinal haemorrhage—Doxorubicin—pancreatic cancer	0.000159	0.00109	CcSEcCtD
Dabigatran etexilate—Pain in extremity—Doxorubicin—pancreatic cancer	0.000159	0.00109	CcSEcCtD
Dabigatran etexilate—Osteoarthritis—Doxorubicin—pancreatic cancer	0.000159	0.00109	CcSEcCtD
Dabigatran etexilate—Mediastinal disorder—Docetaxel—pancreatic cancer	0.000158	0.00109	CcSEcCtD
Dabigatran etexilate—Liver function test abnormal—Epirubicin—pancreatic cancer	0.000158	0.00109	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Fluorouracil—pancreatic cancer	0.000158	0.00108	CcSEcCtD
Dabigatran etexilate—Asthenia—Sunitinib—pancreatic cancer	0.000157	0.00108	CcSEcCtD
Dabigatran etexilate—Dyspnoea—Gemcitabine—pancreatic cancer	0.000157	0.00108	CcSEcCtD
Dabigatran etexilate—Abdominal pain upper—Epirubicin—pancreatic cancer	0.000157	0.00107	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Irinotecan—pancreatic cancer	0.000156	0.00107	CcSEcCtD
Dabigatran etexilate—Fatigue—Irinotecan—pancreatic cancer	0.000156	0.00107	CcSEcCtD
Dabigatran etexilate—Pruritus—Sunitinib—pancreatic cancer	0.000155	0.00107	CcSEcCtD
Dabigatran etexilate—Constipation—Irinotecan—pancreatic cancer	0.000155	0.00106	CcSEcCtD
Dabigatran etexilate—Aspartate aminotransferase increased—Epirubicin—pancreatic cancer	0.000154	0.00106	CcSEcCtD
Dabigatran etexilate—Dyspnoea—Fluorouracil—pancreatic cancer	0.000154	0.00106	CcSEcCtD
Dabigatran etexilate—Nasopharyngitis—Epirubicin—pancreatic cancer	0.000153	0.00105	CcSEcCtD
Dabigatran etexilate—Malnutrition—Docetaxel—pancreatic cancer	0.000153	0.00105	CcSEcCtD
Dabigatran etexilate—Dyspepsia—Fluorouracil—pancreatic cancer	0.000152	0.00105	CcSEcCtD
Dabigatran etexilate—Nausea—Tamoxifen—pancreatic cancer	0.000152	0.00104	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Gemcitabine—pancreatic cancer	0.000152	0.00104	CcSEcCtD
Dabigatran etexilate—Fatigue—Gemcitabine—pancreatic cancer	0.000152	0.00104	CcSEcCtD
Dabigatran etexilate—Gastritis—Epirubicin—pancreatic cancer	0.000152	0.00104	CcSEcCtD
Dabigatran etexilate—Alanine aminotransferase increased—Epirubicin—pancreatic cancer	0.000151	0.00104	CcSEcCtD
Dabigatran etexilate—Constipation—Gemcitabine—pancreatic cancer	0.000151	0.00103	CcSEcCtD
Dabigatran etexilate—Nausea—Erlotinib—pancreatic cancer	0.000151	0.00103	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Sunitinib—pancreatic cancer	0.00015	0.00103	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Fluorouracil—pancreatic cancer	0.000149	0.00103	CcSEcCtD
Dabigatran etexilate—Influenza—Epirubicin—pancreatic cancer	0.000148	0.00102	CcSEcCtD
Dabigatran etexilate—Dysphagia—Epirubicin—pancreatic cancer	0.000148	0.00102	CcSEcCtD
Dabigatran etexilate—Back pain—Docetaxel—pancreatic cancer	0.000148	0.00102	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Irinotecan—pancreatic cancer	0.000148	0.00101	CcSEcCtD
Dabigatran etexilate—Liver function test abnormal—Doxorubicin—pancreatic cancer	0.000146	0.001	CcSEcCtD
Dabigatran etexilate—Dizziness—Sunitinib—pancreatic cancer	0.000145	0.000995	CcSEcCtD
Dabigatran etexilate—Abdominal pain upper—Doxorubicin—pancreatic cancer	0.000145	0.000994	CcSEcCtD
Dabigatran etexilate—Angina pectoris—Epirubicin—pancreatic cancer	0.000144	0.00099	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Irinotecan—pancreatic cancer	0.000143	0.00098	CcSEcCtD
Dabigatran etexilate—Aspartate aminotransferase increased—Doxorubicin—pancreatic cancer	0.000143	0.00098	CcSEcCtD
Dabigatran etexilate—Bronchitis—Epirubicin—pancreatic cancer	0.000142	0.000978	CcSEcCtD
Dabigatran etexilate—Nasopharyngitis—Doxorubicin—pancreatic cancer	0.000142	0.000973	CcSEcCtD
Dabigatran etexilate—Anaemia—Docetaxel—pancreatic cancer	0.000141	0.000971	CcSEcCtD
Dabigatran etexilate—Gastritis—Doxorubicin—pancreatic cancer	0.00014	0.000963	CcSEcCtD
Dabigatran etexilate—Alanine aminotransferase increased—Doxorubicin—pancreatic cancer	0.00014	0.00096	CcSEcCtD
Dabigatran etexilate—Vomiting—Sunitinib—pancreatic cancer	0.000139	0.000957	CcSEcCtD
Dabigatran etexilate—Rash—Sunitinib—pancreatic cancer	0.000138	0.000949	CcSEcCtD
Dabigatran etexilate—Dermatitis—Sunitinib—pancreatic cancer	0.000138	0.000948	CcSEcCtD
Dabigatran etexilate—Upper respiratory tract infection—Epirubicin—pancreatic cancer	0.000138	0.000945	CcSEcCtD
Dabigatran etexilate—Urticaria—Fluorouracil—pancreatic cancer	0.000137	0.000943	CcSEcCtD
Dabigatran etexilate—Headache—Sunitinib—pancreatic cancer	0.000137	0.000943	CcSEcCtD
Dabigatran etexilate—Syncope—Docetaxel—pancreatic cancer	0.000137	0.000942	CcSEcCtD
Dabigatran etexilate—Influenza—Doxorubicin—pancreatic cancer	0.000137	0.000941	CcSEcCtD
Dabigatran etexilate—Dysphagia—Doxorubicin—pancreatic cancer	0.000137	0.000941	CcSEcCtD
Dabigatran etexilate—Palpitations—Docetaxel—pancreatic cancer	0.000135	0.000928	CcSEcCtD
Dabigatran etexilate—Loss of consciousness—Docetaxel—pancreatic cancer	0.000135	0.000923	CcSEcCtD
Dabigatran etexilate—Cough—Docetaxel—pancreatic cancer	0.000134	0.000917	CcSEcCtD
Dabigatran etexilate—Angina pectoris—Doxorubicin—pancreatic cancer	0.000134	0.000916	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Irinotecan—pancreatic cancer	0.000133	0.000914	CcSEcCtD
Dabigatran etexilate—Pneumonia—Epirubicin—pancreatic cancer	0.000133	0.000912	CcSEcCtD
Dabigatran etexilate—Hypertension—Docetaxel—pancreatic cancer	0.000132	0.000907	CcSEcCtD
Dabigatran etexilate—Infestation NOS—Epirubicin—pancreatic cancer	0.000132	0.000907	CcSEcCtD
Dabigatran etexilate—Infestation—Epirubicin—pancreatic cancer	0.000132	0.000907	CcSEcCtD
Dabigatran etexilate—Bronchitis—Doxorubicin—pancreatic cancer	0.000132	0.000905	CcSEcCtD
Dabigatran etexilate—Chest pain—Docetaxel—pancreatic cancer	0.00013	0.000894	CcSEcCtD
Dabigatran etexilate—Arthralgia—Docetaxel—pancreatic cancer	0.00013	0.000894	CcSEcCtD
Dabigatran etexilate—Nausea—Sunitinib—pancreatic cancer	0.00013	0.000894	CcSEcCtD
Dabigatran etexilate—Asthenia—Irinotecan—pancreatic cancer	0.00013	0.00089	CcSEcCtD
Dabigatran etexilate—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—pancreatic cancer	0.000129	0.000888	CcSEcCtD
Dabigatran etexilate—Urinary tract infection—Epirubicin—pancreatic cancer	0.000128	0.000881	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Fluorouracil—pancreatic cancer	0.000127	0.000875	CcSEcCtD
Dabigatran etexilate—Upper respiratory tract infection—Doxorubicin—pancreatic cancer	0.000127	0.000874	CcSEcCtD
Dabigatran etexilate—Asthenia—Gemcitabine—pancreatic cancer	0.000126	0.000867	CcSEcCtD
Dabigatran etexilate—Haematuria—Epirubicin—pancreatic cancer	0.000126	0.000864	CcSEcCtD
Dabigatran etexilate—Hepatobiliary disease—Epirubicin—pancreatic cancer	0.000125	0.000857	CcSEcCtD
Dabigatran etexilate—Anaphylactic shock—Docetaxel—pancreatic cancer	0.000125	0.000857	CcSEcCtD
Dabigatran etexilate—Epistaxis—Epirubicin—pancreatic cancer	0.000125	0.000855	CcSEcCtD
Dabigatran etexilate—Pruritus—Gemcitabine—pancreatic cancer	0.000125	0.000855	CcSEcCtD
Dabigatran etexilate—Infection—Docetaxel—pancreatic cancer	0.000124	0.000852	CcSEcCtD
Dabigatran etexilate—Sinusitis—Epirubicin—pancreatic cancer	0.000124	0.00085	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Irinotecan—pancreatic cancer	0.000124	0.000848	CcSEcCtD
Dabigatran etexilate—Pneumonia—Doxorubicin—pancreatic cancer	0.000123	0.000844	CcSEcCtD
Dabigatran etexilate—Shock—Docetaxel—pancreatic cancer	0.000123	0.000843	CcSEcCtD
Dabigatran etexilate—Nervous system disorder—Docetaxel—pancreatic cancer	0.000122	0.000841	CcSEcCtD
Dabigatran etexilate—Pruritus—Fluorouracil—pancreatic cancer	0.000122	0.00084	CcSEcCtD
Dabigatran etexilate—Thrombocytopenia—Docetaxel—pancreatic cancer	0.000122	0.000839	CcSEcCtD
Dabigatran etexilate—Infestation NOS—Doxorubicin—pancreatic cancer	0.000122	0.000839	CcSEcCtD
Dabigatran etexilate—Infestation—Doxorubicin—pancreatic cancer	0.000122	0.000839	CcSEcCtD
Dabigatran etexilate—Skin disorder—Docetaxel—pancreatic cancer	0.000121	0.000833	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Gemcitabine—pancreatic cancer	0.00012	0.000826	CcSEcCtD
Dabigatran etexilate—Dizziness—Irinotecan—pancreatic cancer	0.000119	0.00082	CcSEcCtD
Dabigatran etexilate—Haemoglobin—Epirubicin—pancreatic cancer	0.000119	0.000818	CcSEcCtD
Dabigatran etexilate—Urinary tract infection—Doxorubicin—pancreatic cancer	0.000119	0.000815	CcSEcCtD
Dabigatran etexilate—Haemorrhage—Epirubicin—pancreatic cancer	0.000119	0.000814	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Fluorouracil—pancreatic cancer	0.000118	0.000813	CcSEcCtD
Dabigatran etexilate—Urinary tract disorder—Epirubicin—pancreatic cancer	0.000117	0.000804	CcSEcCtD
Dabigatran etexilate—Oedema peripheral—Epirubicin—pancreatic cancer	0.000117	0.000802	CcSEcCtD
Dabigatran etexilate—Hypotension—Docetaxel—pancreatic cancer	0.000117	0.000801	CcSEcCtD
Dabigatran etexilate—Haematuria—Doxorubicin—pancreatic cancer	0.000117	0.0008	CcSEcCtD
Dabigatran etexilate—Connective tissue disorder—Epirubicin—pancreatic cancer	0.000117	0.0008	CcSEcCtD
Dabigatran etexilate—Urethral disorder—Epirubicin—pancreatic cancer	0.000116	0.000798	CcSEcCtD
Dabigatran etexilate—Hepatobiliary disease—Doxorubicin—pancreatic cancer	0.000116	0.000793	CcSEcCtD
Dabigatran etexilate—Epistaxis—Doxorubicin—pancreatic cancer	0.000115	0.000791	CcSEcCtD
Dabigatran etexilate—Vomiting—Irinotecan—pancreatic cancer	0.000115	0.000788	CcSEcCtD
Dabigatran etexilate—Sinusitis—Doxorubicin—pancreatic cancer	0.000115	0.000787	CcSEcCtD
Dabigatran etexilate—Dizziness—Fluorouracil—pancreatic cancer	0.000114	0.000785	CcSEcCtD
Dabigatran etexilate—Rash—Irinotecan—pancreatic cancer	0.000114	0.000782	CcSEcCtD
Dabigatran etexilate—Dermatitis—Irinotecan—pancreatic cancer	0.000114	0.000781	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	0.000114	0.000781	CcSEcCtD
Dabigatran etexilate—Headache—Irinotecan—pancreatic cancer	0.000113	0.000777	CcSEcCtD
Dabigatran etexilate—Vomiting—Gemcitabine—pancreatic cancer	0.000112	0.000768	CcSEcCtD
Dabigatran etexilate—Dyspnoea—Docetaxel—pancreatic cancer	0.000111	0.000764	CcSEcCtD
Dabigatran etexilate—Rash—Gemcitabine—pancreatic cancer	0.000111	0.000762	CcSEcCtD
Dabigatran etexilate—Dermatitis—Gemcitabine—pancreatic cancer	0.000111	0.000761	CcSEcCtD
Dabigatran etexilate—Haemoglobin—Doxorubicin—pancreatic cancer	0.00011	0.000757	CcSEcCtD
Dabigatran etexilate—Headache—Gemcitabine—pancreatic cancer	0.00011	0.000757	CcSEcCtD
Dabigatran etexilate—Cardiac disorder—Epirubicin—pancreatic cancer	0.00011	0.000755	CcSEcCtD
Dabigatran etexilate—Vomiting—Fluorouracil—pancreatic cancer	0.00011	0.000755	CcSEcCtD
Dabigatran etexilate—Dyspepsia—Docetaxel—pancreatic cancer	0.00011	0.000755	CcSEcCtD
Dabigatran etexilate—Haemorrhage—Doxorubicin—pancreatic cancer	0.00011	0.000753	CcSEcCtD
Dabigatran etexilate—Rash—Fluorouracil—pancreatic cancer	0.000109	0.000749	CcSEcCtD
Dabigatran etexilate—Dermatitis—Fluorouracil—pancreatic cancer	0.000109	0.000748	CcSEcCtD
Dabigatran etexilate—Headache—Fluorouracil—pancreatic cancer	0.000108	0.000744	CcSEcCtD
Dabigatran etexilate—Urinary tract disorder—Doxorubicin—pancreatic cancer	0.000108	0.000744	CcSEcCtD
Dabigatran etexilate—Oedema peripheral—Doxorubicin—pancreatic cancer	0.000108	0.000742	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Docetaxel—pancreatic cancer	0.000108	0.00074	CcSEcCtD
Dabigatran etexilate—Connective tissue disorder—Doxorubicin—pancreatic cancer	0.000108	0.00074	CcSEcCtD
Dabigatran etexilate—Fatigue—Docetaxel—pancreatic cancer	0.000108	0.000739	CcSEcCtD
Dabigatran etexilate—Angiopathy—Epirubicin—pancreatic cancer	0.000108	0.000738	CcSEcCtD
Dabigatran etexilate—Urethral disorder—Doxorubicin—pancreatic cancer	0.000108	0.000738	CcSEcCtD
Dabigatran etexilate—Nausea—Irinotecan—pancreatic cancer	0.000107	0.000737	CcSEcCtD
Dabigatran etexilate—Immune system disorder—Epirubicin—pancreatic cancer	0.000107	0.000735	CcSEcCtD
Dabigatran etexilate—Mediastinal disorder—Epirubicin—pancreatic cancer	0.000107	0.000733	CcSEcCtD
Dabigatran etexilate—Constipation—Docetaxel—pancreatic cancer	0.000107	0.000733	CcSEcCtD
Dabigatran etexilate—Nausea—Gemcitabine—pancreatic cancer	0.000105	0.000717	CcSEcCtD
Dabigatran etexilate—Malnutrition—Epirubicin—pancreatic cancer	0.000103	0.000708	CcSEcCtD
Dabigatran etexilate—Nausea—Fluorouracil—pancreatic cancer	0.000103	0.000705	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Docetaxel—pancreatic cancer	0.000102	0.000701	CcSEcCtD
Dabigatran etexilate—Cardiac disorder—Doxorubicin—pancreatic cancer	0.000102	0.000699	CcSEcCtD
Dabigatran etexilate—Flatulence—Epirubicin—pancreatic cancer	0.000102	0.000698	CcSEcCtD
Dabigatran etexilate—Back pain—Epirubicin—pancreatic cancer	9.99e-05	0.000685	CcSEcCtD
Dabigatran etexilate—Angiopathy—Doxorubicin—pancreatic cancer	9.95e-05	0.000683	CcSEcCtD
Dabigatran etexilate—Immune system disorder—Doxorubicin—pancreatic cancer	9.91e-05	0.00068	CcSEcCtD
Dabigatran etexilate—Mediastinal disorder—Doxorubicin—pancreatic cancer	9.89e-05	0.000679	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Docetaxel—pancreatic cancer	9.87e-05	0.000678	CcSEcCtD
Dabigatran etexilate—Malnutrition—Doxorubicin—pancreatic cancer	9.55e-05	0.000655	CcSEcCtD
Dabigatran etexilate—Anaemia—Epirubicin—pancreatic cancer	9.54e-05	0.000655	CcSEcCtD
Dabigatran etexilate—Flatulence—Doxorubicin—pancreatic cancer	9.41e-05	0.000646	CcSEcCtD
Dabigatran etexilate—Syncope—Epirubicin—pancreatic cancer	9.26e-05	0.000635	CcSEcCtD
Dabigatran etexilate—Back pain—Doxorubicin—pancreatic cancer	9.24e-05	0.000634	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Docetaxel—pancreatic cancer	9.2e-05	0.000632	CcSEcCtD
Dabigatran etexilate—Palpitations—Epirubicin—pancreatic cancer	9.12e-05	0.000626	CcSEcCtD
Dabigatran etexilate—Loss of consciousness—Epirubicin—pancreatic cancer	9.07e-05	0.000623	CcSEcCtD
Dabigatran etexilate—Cough—Epirubicin—pancreatic cancer	9.01e-05	0.000618	CcSEcCtD
Dabigatran etexilate—Asthenia—Docetaxel—pancreatic cancer	8.96e-05	0.000615	CcSEcCtD
Dabigatran etexilate—Hypertension—Epirubicin—pancreatic cancer	8.91e-05	0.000612	CcSEcCtD
Dabigatran etexilate—Pruritus—Docetaxel—pancreatic cancer	8.84e-05	0.000606	CcSEcCtD
Dabigatran etexilate—Anaemia—Doxorubicin—pancreatic cancer	8.83e-05	0.000606	CcSEcCtD
Dabigatran etexilate—Arthralgia—Epirubicin—pancreatic cancer	8.79e-05	0.000603	CcSEcCtD
Dabigatran etexilate—Chest pain—Epirubicin—pancreatic cancer	8.79e-05	0.000603	CcSEcCtD
Dabigatran etexilate—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	8.73e-05	0.000599	CcSEcCtD
Dabigatran etexilate—Syncope—Doxorubicin—pancreatic cancer	8.57e-05	0.000588	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Docetaxel—pancreatic cancer	8.55e-05	0.000586	CcSEcCtD
Dabigatran etexilate—Palpitations—Doxorubicin—pancreatic cancer	8.44e-05	0.000579	CcSEcCtD
Dabigatran etexilate—Anaphylactic shock—Epirubicin—pancreatic cancer	8.42e-05	0.000578	CcSEcCtD
Dabigatran etexilate—Loss of consciousness—Doxorubicin—pancreatic cancer	8.39e-05	0.000576	CcSEcCtD
Dabigatran etexilate—Infection—Epirubicin—pancreatic cancer	8.37e-05	0.000574	CcSEcCtD
Dabigatran etexilate—Cough—Doxorubicin—pancreatic cancer	8.33e-05	0.000572	CcSEcCtD
Dabigatran etexilate—Shock—Epirubicin—pancreatic cancer	8.29e-05	0.000569	CcSEcCtD
Dabigatran etexilate—Nervous system disorder—Epirubicin—pancreatic cancer	8.26e-05	0.000567	CcSEcCtD
Dabigatran etexilate—Dizziness—Docetaxel—pancreatic cancer	8.26e-05	0.000567	CcSEcCtD
Dabigatran etexilate—Thrombocytopenia—Epirubicin—pancreatic cancer	8.25e-05	0.000566	CcSEcCtD
Dabigatran etexilate—Hypertension—Doxorubicin—pancreatic cancer	8.25e-05	0.000566	CcSEcCtD
Dabigatran etexilate—Skin disorder—Epirubicin—pancreatic cancer	8.18e-05	0.000562	CcSEcCtD
Dabigatran etexilate—Chest pain—Doxorubicin—pancreatic cancer	8.13e-05	0.000558	CcSEcCtD
Dabigatran etexilate—Arthralgia—Doxorubicin—pancreatic cancer	8.13e-05	0.000558	CcSEcCtD
Dabigatran etexilate—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	8.08e-05	0.000554	CcSEcCtD
Dabigatran etexilate—Vomiting—Docetaxel—pancreatic cancer	7.94e-05	0.000545	CcSEcCtD
Dabigatran etexilate—Rash—Docetaxel—pancreatic cancer	7.88e-05	0.00054	CcSEcCtD
Dabigatran etexilate—Hypotension—Epirubicin—pancreatic cancer	7.87e-05	0.00054	CcSEcCtD
Dabigatran etexilate—Dermatitis—Docetaxel—pancreatic cancer	7.87e-05	0.00054	CcSEcCtD
Dabigatran etexilate—Headache—Docetaxel—pancreatic cancer	7.82e-05	0.000537	CcSEcCtD
Dabigatran etexilate—Anaphylactic shock—Doxorubicin—pancreatic cancer	7.8e-05	0.000535	CcSEcCtD
Dabigatran etexilate—Infection—Doxorubicin—pancreatic cancer	7.74e-05	0.000531	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	7.68e-05	0.000527	CcSEcCtD
Dabigatran etexilate—Shock—Doxorubicin—pancreatic cancer	7.67e-05	0.000526	CcSEcCtD
Dabigatran etexilate—Nervous system disorder—Doxorubicin—pancreatic cancer	7.64e-05	0.000525	CcSEcCtD
Dabigatran etexilate—Thrombocytopenia—Doxorubicin—pancreatic cancer	7.63e-05	0.000524	CcSEcCtD
Dabigatran etexilate—Skin disorder—Doxorubicin—pancreatic cancer	7.57e-05	0.00052	CcSEcCtD
Dabigatran etexilate—Dyspnoea—Epirubicin—pancreatic cancer	7.51e-05	0.000515	CcSEcCtD
Dabigatran etexilate—Nausea—Docetaxel—pancreatic cancer	7.42e-05	0.000509	CcSEcCtD
Dabigatran etexilate—Dyspepsia—Epirubicin—pancreatic cancer	7.42e-05	0.000509	CcSEcCtD
Dabigatran etexilate—Hypotension—Doxorubicin—pancreatic cancer	7.28e-05	0.0005	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Epirubicin—pancreatic cancer	7.27e-05	0.000499	CcSEcCtD
Dabigatran etexilate—Fatigue—Epirubicin—pancreatic cancer	7.26e-05	0.000498	CcSEcCtD
Dabigatran etexilate—Constipation—Epirubicin—pancreatic cancer	7.2e-05	0.000494	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	7.1e-05	0.000487	CcSEcCtD
Dabigatran etexilate—Dyspnoea—Doxorubicin—pancreatic cancer	6.95e-05	0.000477	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Epirubicin—pancreatic cancer	6.89e-05	0.000473	CcSEcCtD
Dabigatran etexilate—Dyspepsia—Doxorubicin—pancreatic cancer	6.86e-05	0.000471	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	6.73e-05	0.000462	CcSEcCtD
Dabigatran etexilate—Fatigue—Doxorubicin—pancreatic cancer	6.72e-05	0.000461	CcSEcCtD
Dabigatran etexilate—Urticaria—Epirubicin—pancreatic cancer	6.69e-05	0.000459	CcSEcCtD
Dabigatran etexilate—Constipation—Doxorubicin—pancreatic cancer	6.67e-05	0.000457	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Epirubicin—pancreatic cancer	6.66e-05	0.000457	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Doxorubicin—pancreatic cancer	6.37e-05	0.000437	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Epirubicin—pancreatic cancer	6.21e-05	0.000426	CcSEcCtD
Dabigatran etexilate—Urticaria—Doxorubicin—pancreatic cancer	6.19e-05	0.000425	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Doxorubicin—pancreatic cancer	6.16e-05	0.000423	CcSEcCtD
Dabigatran etexilate—F2—GPCR downstream signaling—GLP1R—pancreatic cancer	6.08e-05	0.000855	CbGpPWpGaD
Dabigatran etexilate—Asthenia—Epirubicin—pancreatic cancer	6.04e-05	0.000415	CcSEcCtD
Dabigatran etexilate—F2—GPCR downstream signaling—CCKAR—pancreatic cancer	5.98e-05	0.000841	CbGpPWpGaD
Dabigatran etexilate—Pruritus—Epirubicin—pancreatic cancer	5.96e-05	0.000409	CcSEcCtD
Dabigatran etexilate—UGT2B7—Metabolism—PRSS1—pancreatic cancer	5.95e-05	0.000838	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—SCT—pancreatic cancer	5.93e-05	0.000835	CbGpPWpGaD
Dabigatran etexilate—F2—Platelet activation, signaling and aggregation—PIK3CB—pancreatic cancer	5.88e-05	0.000828	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—CD44—pancreatic cancer	5.77e-05	0.000812	CbGpPWpGaD
Dabigatran etexilate—Diarrhoea—Epirubicin—pancreatic cancer	5.76e-05	0.000396	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Doxorubicin—pancreatic cancer	5.74e-05	0.000394	CcSEcCtD
Dabigatran etexilate—F2—Signaling Pathways—PRLHR—pancreatic cancer	5.67e-05	0.000799	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—CCK—pancreatic cancer	5.66e-05	0.000797	CbGpPWpGaD
Dabigatran etexilate—F2—Regulation of Actin Cytoskeleton—EGFR—pancreatic cancer	5.66e-05	0.000797	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—EZH2—pancreatic cancer	5.64e-05	0.000794	CbGpPWpGaD
Dabigatran etexilate—Asthenia—Doxorubicin—pancreatic cancer	5.59e-05	0.000384	CcSEcCtD
Dabigatran etexilate—Dizziness—Epirubicin—pancreatic cancer	5.57e-05	0.000382	CcSEcCtD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—GADD45A—pancreatic cancer	5.55e-05	0.000781	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—GCG—pancreatic cancer	5.53e-05	0.000779	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—CNR2—pancreatic cancer	5.52e-05	0.000777	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—GLP1R—pancreatic cancer	5.52e-05	0.000777	CbGpPWpGaD
Dabigatran etexilate—Pruritus—Doxorubicin—pancreatic cancer	5.52e-05	0.000378	CcSEcCtD
Dabigatran etexilate—UGT2B7—NRF2 pathway—TGFB1—pancreatic cancer	5.47e-05	0.000771	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—CCKAR—pancreatic cancer	5.43e-05	0.000764	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—IAPP—pancreatic cancer	5.38e-05	0.000758	CbGpPWpGaD
Dabigatran etexilate—Vomiting—Epirubicin—pancreatic cancer	5.36e-05	0.000368	CcSEcCtD
Dabigatran etexilate—F2—Regulation of Actin Cytoskeleton—KRAS—pancreatic cancer	5.35e-05	0.000753	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—ACVR1B—pancreatic cancer	5.33e-05	0.000751	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—ZNRF3—pancreatic cancer	5.33e-05	0.000751	CbGpPWpGaD
Dabigatran etexilate—Diarrhoea—Doxorubicin—pancreatic cancer	5.33e-05	0.000366	CcSEcCtD
Dabigatran etexilate—Rash—Epirubicin—pancreatic cancer	5.31e-05	0.000365	CcSEcCtD
Dabigatran etexilate—Dermatitis—Epirubicin—pancreatic cancer	5.31e-05	0.000364	CcSEcCtD
Dabigatran etexilate—Headache—Epirubicin—pancreatic cancer	5.28e-05	0.000362	CcSEcCtD
Dabigatran etexilate—F2—Metabolism of proteins—GCG—pancreatic cancer	5.24e-05	0.000738	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—STK11—pancreatic cancer	5.2e-05	0.000732	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—PTHLH—pancreatic cancer	5.17e-05	0.000727	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—ARG2—pancreatic cancer	5.16e-05	0.000726	CbGpPWpGaD
Dabigatran etexilate—Dizziness—Doxorubicin—pancreatic cancer	5.15e-05	0.000354	CcSEcCtD
Dabigatran etexilate—Nausea—Epirubicin—pancreatic cancer	5e-05	0.000343	CcSEcCtD
Dabigatran etexilate—Vomiting—Doxorubicin—pancreatic cancer	4.96e-05	0.00034	CcSEcCtD
Dabigatran etexilate—F2—Signaling by GPCR—SHH—pancreatic cancer	4.95e-05	0.000697	CbGpPWpGaD
Dabigatran etexilate—Rash—Doxorubicin—pancreatic cancer	4.91e-05	0.000337	CcSEcCtD
Dabigatran etexilate—F2—Regulation of Actin Cytoskeleton—PIK3CA—pancreatic cancer	4.91e-05	0.000692	CbGpPWpGaD
Dabigatran etexilate—Dermatitis—Doxorubicin—pancreatic cancer	4.91e-05	0.000337	CcSEcCtD
Dabigatran etexilate—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—pancreatic cancer	4.9e-05	0.00069	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—IAPP—pancreatic cancer	4.89e-05	0.000688	CbGpPWpGaD
Dabigatran etexilate—Headache—Doxorubicin—pancreatic cancer	4.88e-05	0.000335	CcSEcCtD
Dabigatran etexilate—UGT1A9—Metabolism—PRSS1—pancreatic cancer	4.84e-05	0.000681	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—DTX1—pancreatic cancer	4.82e-05	0.000679	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—SSTR3—pancreatic cancer	4.82e-05	0.000679	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—STK11—pancreatic cancer	4.75e-05	0.000669	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—SST—pancreatic cancer	4.72e-05	0.000665	CbGpPWpGaD
Dabigatran etexilate—F2—Platelet activation, signaling and aggregation—SRC—pancreatic cancer	4.71e-05	0.000663	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—PTHLH—pancreatic cancer	4.69e-05	0.00066	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—PTCH1—pancreatic cancer	4.69e-05	0.00066	CbGpPWpGaD
Dabigatran etexilate—F2—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—pancreatic cancer	4.63e-05	0.000652	CbGpPWpGaD
Dabigatran etexilate—Nausea—Doxorubicin—pancreatic cancer	4.63e-05	0.000318	CcSEcCtD
Dabigatran etexilate—F2—Signaling Pathways—SSTR1—pancreatic cancer	4.63e-05	0.000651	CbGpPWpGaD
Dabigatran etexilate—F2—Platelet activation, signaling and aggregation—VEGFA—pancreatic cancer	4.59e-05	0.000646	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PPY—pancreatic cancer	4.54e-05	0.000639	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—TYMP—pancreatic cancer	4.51e-05	0.000635	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—TYMS—pancreatic cancer	4.47e-05	0.00063	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Allograft Rejection—CXCL8—pancreatic cancer	4.47e-05	0.00063	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—SSTR2—pancreatic cancer	4.45e-05	0.000627	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—NRF2 pathway—TGFB1—pancreatic cancer	4.45e-05	0.000626	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—PLAU—pancreatic cancer	4.45e-05	0.000626	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—CNR1—pancreatic cancer	4.36e-05	0.000614	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CCKBR—pancreatic cancer	4.3e-05	0.000605	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA2—pancreatic cancer	4.29e-05	0.000605	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—SST—pancreatic cancer	4.29e-05	0.000604	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Allograft Rejection—CASP3—pancreatic cancer	4.28e-05	0.000603	CbGpPWpGaD
Dabigatran etexilate—F2—Class A/1 (Rhodopsin-like receptors)—CXCL8—pancreatic cancer	4.28e-05	0.000602	CbGpPWpGaD
Dabigatran etexilate—F2—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—pancreatic cancer	4.22e-05	0.000594	CbGpPWpGaD
Dabigatran etexilate—F2—Platelet activation, signaling and aggregation—TGFB1—pancreatic cancer	4.21e-05	0.000593	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—GCG—pancreatic cancer	4.21e-05	0.000593	CbGpPWpGaD
Dabigatran etexilate—ABCB1—HIF-1-alpha transcription factor network—VEGFA—pancreatic cancer	4.2e-05	0.000591	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—ARG2—pancreatic cancer	4.19e-05	0.00059	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—SMAD4—pancreatic cancer	4.16e-05	0.000586	CbGpPWpGaD
Dabigatran etexilate—F2—G alpha (q) signalling events—PIK3CA—pancreatic cancer	4.1e-05	0.000577	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—TYMS—pancreatic cancer	4.08e-05	0.000575	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—GLI1—pancreatic cancer	4.04e-05	0.000569	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—DTX4—pancreatic cancer	4.04e-05	0.000569	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—AGTR1—pancreatic cancer	4.02e-05	0.000566	CbGpPWpGaD
Dabigatran etexilate—F2—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—pancreatic cancer	3.99e-05	0.000562	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—CNR1—pancreatic cancer	3.96e-05	0.000557	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—PIK3CG—pancreatic cancer	3.96e-05	0.000557	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PPP2R5B—pancreatic cancer	3.93e-05	0.000554	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—NRP1—pancreatic cancer	3.93e-05	0.000554	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—EGF—pancreatic cancer	3.91e-05	0.00055	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—GCG—pancreatic cancer	3.82e-05	0.000538	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—HEY2—pancreatic cancer	3.79e-05	0.000533	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—GAST—pancreatic cancer	3.7e-05	0.000521	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—TYMP—pancreatic cancer	3.66e-05	0.000516	CbGpPWpGaD
Dabigatran etexilate—F2—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—pancreatic cancer	3.66e-05	0.000516	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—AGTR1—pancreatic cancer	3.65e-05	0.000514	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—APOE—pancreatic cancer	3.64e-05	0.000512	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—GLP1R—pancreatic cancer	3.63e-05	0.000512	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Allograft Rejection—VEGFA—pancreatic cancer	3.63e-05	0.000512	CbGpPWpGaD
Dabigatran etexilate—F2—Platelet activation, signaling and aggregation—PIK3CA—pancreatic cancer	3.58e-05	0.000505	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—DPYD—pancreatic cancer	3.58e-05	0.000503	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—SCT—pancreatic cancer	3.51e-05	0.000494	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—HEY1—pancreatic cancer	3.51e-05	0.000494	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—PIK3CD—pancreatic cancer	3.48e-05	0.00049	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—SLC2A2—pancreatic cancer	3.39e-05	0.000478	CbGpPWpGaD
Dabigatran etexilate—F2—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—pancreatic cancer	3.39e-05	0.000477	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CCK—pancreatic cancer	3.34e-05	0.000471	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Allograft Rejection—TGFB1—pancreatic cancer	3.33e-05	0.00047	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—PIK3CG—pancreatic cancer	3.28e-05	0.000462	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CNR2—pancreatic cancer	3.26e-05	0.000459	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—GLP1R—pancreatic cancer	3.26e-05	0.000459	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR ligand binding—CXCL8—pancreatic cancer	3.26e-05	0.000459	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CCKAR—pancreatic cancer	3.21e-05	0.000451	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—PPARG—pancreatic cancer	3.17e-05	0.000446	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Allograft Rejection—TNF—pancreatic cancer	3.11e-05	0.000438	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—JAG2—pancreatic cancer	3.11e-05	0.000438	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—NFKBIA—pancreatic cancer	3.1e-05	0.000436	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—MEN1—pancreatic cancer	3.06e-05	0.000431	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—PIK3CB—pancreatic cancer	3.03e-05	0.000427	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—APOE—pancreatic cancer	3.02e-05	0.000426	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—EGF—pancreatic cancer	2.96e-05	0.000417	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—GLP1R—pancreatic cancer	2.95e-05	0.000416	CbGpPWpGaD
Dabigatran etexilate—F2—Platelet activation, signaling and aggregation—AKT1—pancreatic cancer	2.93e-05	0.000412	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—SHH—pancreatic cancer	2.92e-05	0.000412	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—DPYD—pancreatic cancer	2.91e-05	0.000409	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—NOTCH4—pancreatic cancer	2.9e-05	0.000409	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—IAPP—pancreatic cancer	2.89e-05	0.000406	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—PIK3CD—pancreatic cancer	2.89e-05	0.000406	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PTHLH—pancreatic cancer	2.77e-05	0.00039	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PTCH1—pancreatic cancer	2.77e-05	0.00039	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—SLC2A2—pancreatic cancer	2.76e-05	0.000388	CbGpPWpGaD
Dabigatran etexilate—F2—Metabolism of proteins—MMP2—pancreatic cancer	2.76e-05	0.000388	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CG—pancreatic cancer	2.73e-05	0.000384	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—SLC2A2—pancreatic cancer	2.7e-05	0.00038	CbGpPWpGaD
Dabigatran etexilate—ABCB1—HIF-1-alpha transcription factor network—AKT1—pancreatic cancer	2.68e-05	0.000377	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—PPARG—pancreatic cancer	2.63e-05	0.000371	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—CD44—pancreatic cancer	2.63e-05	0.00037	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—SST—pancreatic cancer	2.53e-05	0.000357	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—GCG—pancreatic cancer	2.52e-05	0.000355	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—PIK3CB—pancreatic cancer	2.52e-05	0.000354	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—PIK3CG—pancreatic cancer	2.5e-05	0.000352	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—PTGS2—pancreatic cancer	2.49e-05	0.000351	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—JAG1—pancreatic cancer	2.48e-05	0.000349	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—NOTCH3—pancreatic cancer	2.47e-05	0.000348	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—SRC—pancreatic cancer	2.43e-05	0.000342	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	2.4e-05	0.000338	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—STK11—pancreatic cancer	2.37e-05	0.000334	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—VEGFA—pancreatic cancer	2.37e-05	0.000333	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CNR1—pancreatic cancer	2.34e-05	0.000329	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—NRAS—pancreatic cancer	2.34e-05	0.000329	CbGpPWpGaD
Dabigatran etexilate—F2—Metabolism of proteins—CXCL8—pancreatic cancer	2.29e-05	0.000323	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—pancreatic cancer	2.28e-05	0.00032	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—PIK3CG—pancreatic cancer	2.27e-05	0.00032	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—GCG—pancreatic cancer	2.26e-05	0.000318	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PRSS1—pancreatic cancer	2.22e-05	0.000312	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—PIK3CD—pancreatic cancer	2.2e-05	0.000309	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—PTEN—pancreatic cancer	2.17e-05	0.000306	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—TGFB1—pancreatic cancer	2.17e-05	0.000306	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—AGTR1—pancreatic cancer	2.15e-05	0.000303	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—CD44—pancreatic cancer	2.14e-05	0.000301	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—STK11—pancreatic cancer	2.12e-05	0.000299	CbGpPWpGaD
Dabigatran etexilate—F2—Metabolism of proteins—CTNNB1—pancreatic cancer	2.11e-05	0.000298	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—pancreatic cancer	2.11e-05	0.000297	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	2.09e-05	0.000294	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	2.07e-05	0.000292	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—pancreatic cancer	2.06e-05	0.00029	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—GCG—pancreatic cancer	2.05e-05	0.000288	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—TYMS—pancreatic cancer	2.04e-05	0.000287	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—pancreatic cancer	2.04e-05	0.000287	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—KRAS—pancreatic cancer	2.01e-05	0.000283	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—PIK3CD—pancreatic cancer	2e-05	0.000281	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—pancreatic cancer	1.99e-05	0.000279	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—STK11—pancreatic cancer	1.92e-05	0.000271	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—ARG2—pancreatic cancer	1.92e-05	0.000271	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—PIK3CB—pancreatic cancer	1.92e-05	0.00027	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—SMAD4—pancreatic cancer	1.86e-05	0.000262	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—PIK3CA—pancreatic cancer	1.85e-05	0.00026	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—pancreatic cancer	1.84e-05	0.000259	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—CXCL8—pancreatic cancer	1.84e-05	0.000259	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—HES1—pancreatic cancer	1.82e-05	0.000256	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	1.81e-05	0.000254	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—pancreatic cancer	1.79e-05	0.000252	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—TP53—pancreatic cancer	1.79e-05	0.000252	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—PIK3CB—pancreatic cancer	1.74e-05	0.000245	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—HRAS—pancreatic cancer	1.71e-05	0.000241	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—TYMP—pancreatic cancer	1.68e-05	0.000237	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—CXCL8—pancreatic cancer	1.67e-05	0.000235	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—APOE—pancreatic cancer	1.66e-05	0.000233	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—TYMS—pancreatic cancer	1.66e-05	0.000233	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—pancreatic cancer	1.65e-05	0.000232	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—pancreatic cancer	1.65e-05	0.000232	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—pancreatic cancer	1.61e-05	0.000227	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—TERT—pancreatic cancer	1.59e-05	0.000224	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—pancreatic cancer	1.54e-05	0.000216	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—PIK3CA—pancreatic cancer	1.53e-05	0.000216	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—pancreatic cancer	1.52e-05	0.000215	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—HIF1A—pancreatic cancer	1.52e-05	0.000214	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—TSC2—pancreatic cancer	1.52e-05	0.000214	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—AKT1—pancreatic cancer	1.51e-05	0.000213	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—PIK3CG—pancreatic cancer	1.5e-05	0.000211	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—APOE—pancreatic cancer	1.49e-05	0.000209	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—KDR—pancreatic cancer	1.46e-05	0.000205	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—PPARG—pancreatic cancer	1.44e-05	0.000203	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—pancreatic cancer	1.4e-05	0.000197	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—NFKBIA—pancreatic cancer	1.38e-05	0.000195	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—NOTCH1—pancreatic cancer	1.37e-05	0.000193	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—GLP1R—pancreatic cancer	1.36e-05	0.000191	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—pancreatic cancer	1.35e-05	0.000191	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—APOE—pancreatic cancer	1.35e-05	0.00019	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PIK3CG—pancreatic cancer	1.34e-05	0.000189	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—NRAS—pancreatic cancer	1.34e-05	0.000189	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—DPYD—pancreatic cancer	1.33e-05	0.000188	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—EGF—pancreatic cancer	1.33e-05	0.000187	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—PIK3CD—pancreatic cancer	1.31e-05	0.000185	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	1.27e-05	0.000179	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—SLC2A2—pancreatic cancer	1.26e-05	0.000178	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—AKT1—pancreatic cancer	1.25e-05	0.000176	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—EGFR—pancreatic cancer	1.22e-05	0.000172	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—PIK3CG—pancreatic cancer	1.22e-05	0.000171	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PIK3CD—pancreatic cancer	1.18e-05	0.000166	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—PPARG—pancreatic cancer	1.17e-05	0.000165	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—PIK3CA—pancreatic cancer	1.17e-05	0.000164	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—KRAS—pancreatic cancer	1.15e-05	0.000162	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—PIK3CB—pancreatic cancer	1.15e-05	0.000161	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—pancreatic cancer	1.14e-05	0.000161	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—PTGS2—pancreatic cancer	1.14e-05	0.00016	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—PIK3CD—pancreatic cancer	1.07e-05	0.00015	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—PIK3CA—pancreatic cancer	1.06e-05	0.000149	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PIK3CB—pancreatic cancer	1.03e-05	0.000145	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—PTEN—pancreatic cancer	9.9e-06	0.000139	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CXCL8—pancreatic cancer	9.87e-06	0.000139	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—HRAS—pancreatic cancer	9.81e-06	0.000138	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—CD44—pancreatic cancer	9.8e-06	0.000138	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—AKT1—pancreatic cancer	9.54e-06	0.000134	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CASP3—pancreatic cancer	9.45e-06	0.000133	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—GCG—pancreatic cancer	9.39e-06	0.000132	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—PIK3CB—pancreatic cancer	9.31e-06	0.000131	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—PTGS2—pancreatic cancer	9.23e-06	0.00013	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CCND1—pancreatic cancer	9.2e-06	0.00013	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CTNNB1—pancreatic cancer	9.11e-06	0.000128	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—MMP9—pancreatic cancer	8.93e-06	0.000126	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PTEN—pancreatic cancer	8.88e-06	0.000125	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—STK11—pancreatic cancer	8.83e-06	0.000124	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—AKT1—pancreatic cancer	8.66e-06	0.000122	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—SRC—pancreatic cancer	8.23e-06	0.000116	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—PTEN—pancreatic cancer	8.05e-06	0.000113	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—VEGFA—pancreatic cancer	8.02e-06	0.000113	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—STAT3—pancreatic cancer	7.94e-06	0.000112	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—NRAS—pancreatic cancer	7.92e-06	0.000112	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—TYMS—pancreatic cancer	7.6e-06	0.000107	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—MYC—pancreatic cancer	7.38e-06	0.000104	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—TGFB1—pancreatic cancer	7.36e-06	0.000104	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—EGFR—pancreatic cancer	7.22e-06	0.000102	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—PIK3CA—pancreatic cancer	6.99e-06	9.84e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—KRAS—pancreatic cancer	6.82e-06	9.6e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PIK3CA—pancreatic cancer	6.26e-06	8.82e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—APOE—pancreatic cancer	6.18e-06	8.7e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—TP53—pancreatic cancer	6.06e-06	8.53e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—HRAS—pancreatic cancer	5.8e-06	8.16e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—AKT1—pancreatic cancer	5.71e-06	8.04e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—PIK3CA—pancreatic cancer	5.68e-06	7.99e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PIK3CG—pancreatic cancer	5.58e-06	7.85e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PPARG—pancreatic cancer	5.38e-06	7.58e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—AKT1—pancreatic cancer	5.12e-06	7.2e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PIK3CD—pancreatic cancer	4.9e-06	6.9e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—AKT1—pancreatic cancer	4.64e-06	6.53e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PIK3CB—pancreatic cancer	4.27e-06	6.01e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PTGS2—pancreatic cancer	4.23e-06	5.96e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PTEN—pancreatic cancer	3.69e-06	5.2e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PIK3CA—pancreatic cancer	2.6e-06	3.67e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—AKT1—pancreatic cancer	2.13e-06	3e-05	CbGpPWpGaD
